The emergence of dual-action receptor agonists in the treatment of type 2 diabetes and obesity has sparked considerable focus, particularly regarding retatrutide and tirzepatide. While both medications target both the https://graysonvxlz821392.actoblog.com/39625543/retatrutide-vs-tirzepatide-a-comparative-analysis